^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    NB002

    i
    Other names: NB002
    Associations

    News

    Trials
    Company:
    Neologics Biosci
    Drug class:
    TIM-3 inhibitor
    Related drugs:
    Associations

    News

    Trials
    11ms
    A Dose Escalation and Expansion Study of NB002 in Participants With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1a/1b, N=30, Not yet recruiting, Suzhou Neologics Bioscience Co., Ltd.
    New P1 trial • Metastases
    |
    HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
    |
    NB002
    1year
    NB002, a novel therapeutic antibody targeting unique epitope on TIM-3 presenting potent antitumor activity (AACR 2023)
    These data could potentially explain novel features of NB002, restoring both acquired and innate immunity which could lead cold tumor to hot tumor.In summary, these data showed that NB002 is a potent anti-TIM-3 antibody with pre-clinical properties. A phase 1 study is planned and patients with advanced metastatic solid tumors will be recruited.
    PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
    |
    HAVCR2 expression
    |
    NB002